Interleukin 2 and lymphokine-activated killer cells in the treatment of childhood primary hepatocellular carcinoma--a preliminary report.
Recombinant interleukin-2 (RIL-2) and lymphokine-activated killer (LAK) cells were administered to 2 boys with the end-stage of primary hepatocellular carcinoma (HCC); the efficacy and toxicity were evaluated. Immunologically, the natural killer and LAK activities were enhanced. Clinically, the side effects were similar to those reported for adults but milder. This kind of treatment may be considered for children with the early stages of hepatocellular carcinoma.
D006528:Carcinoma, Hepatocellular / Q000628:therapy*; D002648:Child; D006801:Humans; D007262:Infusions, Intravenous; D007376:Interleukin-2 / Q000008:administration & dosage / Q000627:therapeutic use*; D007694:Killer Cells, Natural / Q000276:immunology*; D008113:Liver Neoplasms / Q000628:therapy*; D008213:Lymphocyte Activation; D008222:Lymphokines; D008297:Male; D011994:Recombinant Proteins / Q000627:therapeutic use
D007376:Interleukin-2; D008222:Lymphokines; D011994:Recombinant Proteins